368
Participants
Start Date
August 31, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
Placebo
TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875
TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
Sitagliptin
Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
TAK-875 and Sitagliptin
TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
TAK-875 and Sitagliptin
TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Birmingham
Brimingham
Chandler
Glendale
Green Valley
Mesa
Tempe
Tucson
Buena Park
Irvine
Norwalk
Paramount
Rancho Cucamonga
San Ramon
Spring Valley
Vista
Walnut Creek
Westlake Village
Colorado Springs
Lakewood
Brandon
Clearwater
DeLand
Hallandale
Hialeah
Jupiter
Longwood
Miami
Miami Lakes
Orlando
Pembroke Pines
St. Petersburg
Tampa
Atlanta
Roswell
Suwanee
Boise
Chicago
Valparaiso
Crestview Hills
Lexington
Louisville
Bangor
Elkridge
Brockton
Chelsea
Kalamazoo
Olive Branch
Berlin
Margate City
Toms River
Brooklyn
Buffalo
Calabash
Fuquay-Varina
Morehead City
Winston-Salem
Akron
Cincinnati
Columbus
Lyndhurst
Marion
Willoughby Hills
Oklahoma City
Portland
Broomall
Feasterville
Fleetwood
Cranston
Chattanooga
Crossville
Kingsport
Nashville
Dallas
Houston
Irving
North Richland Hills
Pearland
San Antonio
Seattle
Lead Sponsor
Takeda
INDUSTRY